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The association between female sexual function and hormonal contraception is controversial. Recognition and management of
sexual side effects in women using hormonal contraceptives are challenging. An unsatisfactory number of studies report the
influence of the available contraceptives on female sexuality. This article provides an updated narrative review regarding the effect
and the magnitude of the impact that hormonal contraceptives play in female sexual function.
1. Introduction
Female sexual dysfunction (FSD) takes different forms,
including lack of sexual desire, impaired arousal, inability
to achieve orgasm, or pain with sexual activity. It can be
defined as a persistent or recurrent sexual problem that causes
marked distress or interpersonal difficulty [1]. It may be a
lifelong problem or acquired after a period of normal sexual
function.
Female sexual problems are highly prevalent worldwide.
The prevalence of FSD ranges from 27% to 70% [2–4]. A
population-based study with women aged 18 to 79 years
found that 37.9% of the Portuguese women report symptoms
regarding sexual health [5]. A similar percentage of women
have sexual concerns in the United States [6].
The etiology of FSD is often multifactorial and may
include psychological problems such as depression or anx-
iety, relationship conflict, fatigue, stress, issues relating to
prior physical or sexual abuse, medications, and physical
problems such as endometriosis or genitourinary syndrome
of menopause [7]. Female sexual function is influenced by
several biological, psychological, and social factors.
The general framework sequence of the female sexual
response cycle is described in four phases: desire (libido),
arousal (excitement), orgasm, and resolution [1, 7]. How-
ever, this cycle of responses must be understood within
an intrapersonal and interpersonal context. As previously
mentioned, factors as depression or the length of relationship
have been associated with FSD [8, 9]. For many women, the
contemporary phases of the sexual response cycle may vary
in sequence, overlap, repeat, or even be absent, during all or
some sexual encounters [7, 8].
In fact, a women's subjective satisfaction with the sexual
experience may not require achieving all response phases.
The solid correlation observed in men, between subjective
arousal and genital congestion (erection), is not seen in
women. Most studies identify little correlation between a
woman’s complaints of limited genital arousal and objec-
tive measures of vulvovaginal blood flow and engorgement.
Arousal may relate to physiological phenomena as vaso-
congestion and genital lubrication, and/or to thoughts and
feelings. Self-reports by women often do not distinguish
between desire and arousal. In addition, spontaneous desire
is unusual in women, except in new relationships, which
emphasizes the fact that the absence of this domain does not
necessarily mean a disorder [7, 10].
Low sexual desire is the most commonly reported female
sexual health problem [5, 6]. Significant increases in libido
and in sexual frequency were seen in postmenopausal
women who received weekly intramuscular injections of
testosterone [11]. Sexual desire was significantly associated
with levels of free testosterone (FT) and androstenedione in
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premenopausal women, but FSD in general was not asso-
ciated with androgen levels [9]. A population-based study
of over 1400 randomly selected women aged 18 to 75 years
showed no single androgen level to be predictive of low
sexual function [12].
The female sexual response is complex. The assumption
that androgen levels are a key factor in female sexual function
is based on the role of androgens in male sexuality. Although
exogenous androgens administration exerted a positive bal-
ance on some aspects of female sexuality, in such studies,
however, the levels of circulating testosterone achieved have
been supraphysiological [11, 13, 14].
The biological activity of circulating sex steroids is depen-
dent upon the relative binding to sex hormone-binding
globulin (SHBG).The unbound fraction or FT is biologically
active. 98 percent of circulating testosterone is protein bound,
mainly to SHBG or albumin. Binding to albumin is weak, so
this hormone portion may also be bioavailable [15, 16]. Apart
from the cyclical variation in ovarian androgens, there is not
the same homeostatic regulation of FT levels in women as in
men, and there is a greater variety of factors that are likely
to affect steroid binding in women compared to men (e.g.,
exogenous estrogen) [14, 17].
Hypoestrogenism results in signs and symptoms with
impact on sexual function: reduction of vulvovaginal lubrica-
tion, vasocongestion during sexual arousal, vaginal atrophy,
and dyspareunia [18, 19]. But factors that increase SHBG
concentrations, as estrogen therapy, pregnancy, or oral con-
traceptives (OCs), will decrease FT. However, there is a lack
of evidence that any impact of OCs on sexual function
is caused by decreased androgen activity. And, above all,
there are conflicting data about hormonal contraceptives as
a risk factor for FSD. The relationship between female sexual
function and hormonal contraception is controversial.
This is a narrative review of existing data that explores
the effect and the magnitude of the impact that hormonal
contraceptives play in female sexual function.
2. Contraception and Sexuality
In 1914, a feminist nurse named Margaret Sanger started
believing that women could have reliable contraception. In
1960, “the pill” became reality as a contraceptive approved by
Food andDrugAdministration (FDA). Soon, couples had the
right to engage in nonprocreative sex and the choice of having
children and when to have them.
Today, hormonal contraception is in general an afford-
able, reversible, and highly effective form of family plan-
ning, available with different components (various progestins
and/or estrogens), and with different routes of adminis-
tration. Again, this panoply of possible options reinforces
the right to choose. The woman gained control with these
methods of contraception: control over methods (contrary to
the male condom) and control of sexual availability (despite
the number of days from last menses). The frequency of
sexual activity and sexual enjoyment correlate positively with
contraceptive satisfaction [20]. Fear about an unwanted preg-
nancy was associated with a negative impact on women’s sex-
ual arousal, particularly if one’s partner did not share the same
concern. Although some men often do not consider their
responsibility to think about contraception, somewomen feel
that a partner’s shared concern could serve to buffer potential
negative effects on their ability to feel aroused [21].
Hormonal contraceptives were not thought to improve
sexual function, in addition to the reduction in concern about
the risk of an unplanned pregnancy. However, female contra-
ception has changed sexuality. An unsatisfactory number of
studies report the impact of the available contraceptives on
female sexuality. This is true even for combined oral contra-
ceptives (COCs) introduced half a century ago. Even so, there
are potential consequences for the female sexual response
linked to the various contraceptive methods currently in use,
especially in the case of hormonal contraception. Women's
choice for sexual activity without pregnancy should also be
balanced with the plausible risks and benefits of contracep-
tion for female sexual function.
Sociocultural barriers, taboos, and misconceptions make
the assessment of female sexuality difficult. Clinical, social,
and relationship characteristics of the couplemay also tamper
a correct evaluation of the etiology of sexual dysfunction.
The possible sexual side effects of hormonal contraceptives
are unknown to many patients and are dubious to many
physicians. Challenges in initiating communication on sexual
health continue to be present in clinical practice [22]. How-
ever, it is important that the influence of hormonal methods
upon female sexual function be discussed with women
during contraceptive counseling. Otherwise, omission of the
sexual issues would be counter to the original intent of “the
pill” and therefore could affect the reproductive and sexual
health of users of hormonal contraception.
3. Hormonal Contraceptives and Female
Sexual Function
The association between hormonal contraception and sex-
uality is an important issue of debate and study. Although
there is currently no recommendation to screen for sexual
dysfunction before or during the use of hormonal contra-
ception, various contraceptive methods have been associated
with changes in women’s sexual health. In general, there are
mixed effects on several sexual domains caused by hormonal
contraceptives. There is no consistent pattern regarding route
of administration or estrogen-progestin versus progestin-
only contraceptives.
3.1. Progestin Androgenicity and Estrogen Dose. The endo-
crinology of female sexual function is uncertain. COCs
supress ovarian testosterone levels via suppression of pitu-
itary luteinizing hormone (LH). The estrogen component
of the pill is metabolized in the liver and increases hepatic
production of SHBG, with a consequent decrease in FT
concentrations. Some progestins decrease SHGB levels, but
the overall effect of COCs is an increase in SHBG levels. On
a scale vision, all COCs are antiandrogenic, although some
are more than others depending on the progestin component
[14, 17, 23].
Other hormonal methods can affect SHBG levels as well.
The combined contraceptives, patch and vaginal ring, have
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both been found to increase serum SHBG levels even more
than COCs [24–26].
Also, while a lower ethinylestradiol (EE) contraceptive
pill reduces FT less, higher doses of estrogen do not appear to
increase the likelihood of sexual side effects [27–29]. Indeed,
a prospective randomized study observed the highest rates
of negative impact on sexual well being reported by COC
15 mcg EE users versus 20 mcg EE users [29]. Another
study randomized 97 women to either 30 mcg EE/150 mcg
levonorgestrel (LNG) or 20 mcg EE/100 mcg LNG. Both
groups showed improvements in sexual function, but this was
only with statistical significance for the lower dose group.The
highest dose group decreased plasma androgen levels, but
with no impact on sexual desire. In addition, sexual desire
increased among users of the lower dose formulation [30].
As previously described, it has been proposed that andro-
gens play a role in female sexual function, but correlations
between indices of androgenicity and the various measures of
sexuality are inconsistent. Adouble blind randomized control
trial, comparing effect of drospirenone (DRSP) [3 mg + 30
mcg EE] and gestodene (75 mcg + 20 mcg EE), revealed
significant improvements regarding sexual desire, arousal,
and overall satisfaction in the DRSP group. An increased fre-
quency of orgasms in the gestodene group was reported. And
the diagnosis of FSD and the free androgen index showed
no statistically significant differences between the two treat-
ments [27]. Both OCs formulations, one with an antian-
drogenic activity, the other a non-anti-androgenic progestin,
were not associatedwith negative sexual effects.The relevance
of changes in androgen levels in female sexual function
remains unclear. It seems plausible that some women may be
more susceptible to androgen level alteration than others.
3.2. Short-Acting Reversible Contraception. Long-acting
reversible contraception (LARC) consists of intrauterine
devices (IUDs) and subdermal implants; all other reversible
methods provide shorter-term protection and can be
categorized as short-acting reversible contraception (SARC).
3.2.1. Oral Contraceptives. OCs can be divided into twomain
groups: COCs with estrogen and progestin components and
progestin-only pills (POPs). Contraceptive action is pro-
vided by the inhibition of the hypothalamic-pituitary-ovarian
(HPO) axis, suppressing follicular growth and inhibiting
ovulation. The essential component for any hormonal con-
traceptive method is the progestogen. The primary role of
this component is to prevent ovulation through a nega-
tive feedback mechanism that results in a decrease in LH.
Progestogen action also reduces the receptivity of cervical
mucus and decreases endometrial thickness [31, 32]. Estro-
gens contribute to the contraceptive mechanism by inhibiting
both follicle-stimulating hormone (FSH) and LH. Estrogen
provides better regulation of the HPO axis. The inhibition
of FSH seems to be related to estrogen dose, because more
follicular activity is seenwith progestogen-onlymethods than
with COCs [33, 34].
(1) Combined Oral Contraceptives. COCs remain one of the
most commonly used forms of family planning. Themajority
contain EE as the estrogen component. COCs formulated to
include estradiol (E2) have recently become available for the
indication of pregnancy prevention. A combined estradiol
valerate and dienogest pill (E2V/DNG) and a COC contain-
ing 17𝛽estradiol and nomegestrol acetate (E2/NOMAC) are
the newest alternatives to the first synthetic estrogen.
One of the earliest studies, using two oral contracep-
tives containing the same amount of EE (35 mcg), and an
unvaried dose of norethindrone in a monophasic pill and
a threephase increase in norethindrone in the triphasic pill,
found thatmonophasic users reported less vaginal lubrication
than nonusers, whereas triphasic users did not [35]. Vaginal
dryness was also a side effect of COC reported in a more
recent prospective study, with 280 women randomized in
three groups: (i) taking COC 20 mcg EE/100 mcg LNG, (ii)
COC 15mcg EE/60 mcg gestodene, and (iii) vaginal ring
users (15 mcg EE/120 mcg etonogestrel) [29]. And, overall, a
negative influence on sexual desire was reported by the COC
groups. A similar result was observed in a randomized trial
of a monophasic (35 mcg EE/0.250 mg norgestimate) and
a triphasic pill (35 mcg EE/0.180 mg, 0.215 mg, 0.250 mg
norgestimate), from the Kinsey Institute, which assessed pre-
COC use characteristics at baseline and regularly assessed
womenwith the aim to predict acceptability and continuation
of the pill when used for contraceptive purposes. Of the
subjects who discontinued COCs or switched pills, 8% did
so because of sexual side effects [36]. A statistically significant
decrease in frequency of intercourse and psychosexual arous-
ability was reported.These studies revealed that disturbances
of sexual intercourse are crucial points for acceptability and
compliance [29, 36].
There are quite a few trials that have demonstrated a
negative impact of COCs on female libido. In a cross-
sectional questionnaire study conducted among 349 sex-
ually active community-based women, aged 20-65 years,
the authors found that COCs users had significantly lower
frequencies of sexual thoughts, interest and days of sexual
activity per month, compared to nonusers [37]. A large study
assessing female sexual function and contraception in over
one thousand German medical students, found that COC
users had lower scores on desire and arousal domains, as well
as statistically significant lower total Female Sexual Function
Index (FSFI) scores [38, 39]. (The FSFI is a 19-question tool
covering six domains assessing desire, arousal, orgasm, lubri-
cation, pain and satisfaction. Each domain is associated with
amaximumscore of up to six points out of the total FSFI score
(maximum total score on all domains is 36 points) [40]. The
lower the FSFI score, the higher the likelihood of sexual dys-
function.) As in other studies referenced earlier, once again,
no correlation was found between specific types of COCs
(androgenic or antiandrogenic progestin content, or different
dosages of EE) and negative libido [39]. This absent associa-
tion between a lower FSFI score in COC users, and the pro-
gestin androgenicity and/or the EE dose, was also observed
in a large cohort of 2612 young university women [41].
Furthermore, as already discussed, despite the fact that
COCs decrease bioavailable androgens, several reports have
shown that this decrease does not imply a negative impact on
libido [17, 42, 43]. COC users have reported higher frequency
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of sexual thoughts and interest compared to nonusers [35].
It is also important to reinforce that newer progestogens
like DRSP have been linked to an improvement in sexual
arousal and enjoyment, orgasm frequency, and satisfaction
with sexual activity [44, 45].These results are consistent with
the already mentioned randomized, double-blind, controlled
trial reporting that DRSP did not have an unfavourable effect
on libido [27]. In a multicentre study the majority of women
experienced no change in libido, comparing two COCs with
30mcgEE: (i) associationwithDRSP and (ii) associationwith
LNG, though, in both groups, a small percentage of women
reported higher or lower libido compared with their normal
experience [46]. Another study randomized 115 women to
conventional vs. extended cycle with 20 mcg EE and 3 mg
DRSP, where both groups suffer improvement in several
sexual parametres [47]. Findings suggest that women who
choose a continued-regimenOC should not expect a decrease
in sexual functioning as a result [47, 48].
COCs have been associated with dyspareunia not only
because of possible vaginal dryness, but also because of the
risk of vestibulitis. COC use as a risk factor for provoked
vestibulodynia is another divisive finding in the literature.
Several studies point for an association between COC use
and vestibular pain [49–53].The likelihood of superficial pain
during intercourse seems to be higher when OCs are first
used at a young age and increase with duration of use [50, 52].
However, based on quantitative genital sensory analysis, no
evidencewas found that 20mcgCOCs adversely affect clitoral
or vestibular sensitivity [54]. Other authors also reported that
COC use was not a risk factor for vestibulodynia [55].
Regarding the associations with E2 component in COCs,
there are some interesting studies where some positive sexual
aspects may arise from the use of these pills. A prelimi-
nary study in 57 healthy women showed that E2V/DNG
improved sexual enjoyment, arousal, orgasm, and desire over
six cycles of use; yet, this study was open label, and without
a comparator [56]. Later, a multicenter, randomized, double-
blind study compared the effects of six cycles of E2V/DNG
with EE/LNG on sexual function, in 276 women with COC-
associated sexual dysfunction. Equivalent improvements in
all domains of the FSFI were demonstrated in both groups,
with no significant diferences [57]. Overall, these studies
suggest that E2V/DNG does not have a negative impact on
sexual function.
A recent prospective observational study focused on the
effect of E2/NOMAC to improve the sexual function of
womenwith low sexual desire due to COCusage. At baseline,
the total FSFI score and the Female Sexual Distress Scale
(FSDS) score was measured, both indicating sexual dysfunc-
tion with sexual distress. At the third (first follow-up) and
sixth (second follow-up) COC intake cycles of E2/NOMAC
pill, FSFI score was consistently higher and FSDS score con-
tinued to drop. Interestingly, the previous COCs that women
were using, containing 30 mcg EE and DRSP 3 mg, or chlor-
madinone acetate 2 mg, or dienogest 2 mg, and 20 mcg EE
and DRSP 3 mg, were all progestogens with antiandrogenic
activity. However, there was no comparative COC group in
the study [58]. And the common assumption that COCs con-
taining antiandrogenic progestins have a detrimental effect
on sexual function relative to those containing androgenic
progestins is not irrefutable, quite the contrary [27, 57].
(2) Progestin-Only Pills. Progestin-only methods include pills
and the most commonly used POP in Europe contains
low doses of desogestrel. A placebo-controlled, double-blind
comparison of COCs and POPs users was carried out in two
contrasting cultures (Manila, Philippines, and Edinburgh,
Scotland). All women had been sterilised or partners had
been vasectomised. The POP was associated with no adverse
impact on female sexuality in both centres [59].
3.2.2. Contraceptive Ring, Transdermal Contraceptive Patch,
and Injectable Contraceptive. Other widely used SARCmeth-
ods are the vaginal ring (delivers 15 mcg EE per day) and
the patch (delivers 20 mcg EE per day). The ring contains
etonogestrel and the patch contains norelgestromin as their
progestin component. The injectable contraceptive depot
medroxyprogesterone acetate (DMPA) is a progesterone-only
contraceptive method.
The effects of these other forms of hormonal contracep-
tion on sex drive have not been studied as comprehensively
as OCs. As with COCs, there are conflicting results. In a
randomized study, the better results related to desire and
sexual satisfaction were obtained by vaginal ring users versus
OC users (COC 20 mcg EE/100 mcg LNG and COC 15
mcg EE/60 mcg gestodene) [29]. Improvement of sexual
desire was also noted in women using the contraceptive
ring compared with a desogestrel-containing combined OC
and a desogestrel-only OC [60]. A small prospective study
found that women using the vaginal ring in an extended
manner experienced improvements in sexual function and
reduced sexual distress after 60 days [61]. On the contrary,
an open-label randomized trial compared the contraceptive
ring vs. COC (30 mcg EE + 3 mg DRSP) and observed that a
decreased libido was more common with the ring [62].
Sexual function of first-time users of the contraceptive
ring and contraceptive patch, who had recently used COCs,
was assessed by FSFI scores in a multicentre randomized
study. Slight decrements in sexual function scores were noted
with contraceptive ring use and in several sexual domains,
whereas slight increases were noted with patch use. However,
authors concluded that these changes are not likely to be
clinically significant [63].
Recently, a prospective cohort study, including data from
1983 women aged 14 to 45 years, found less interest in sex in
women using the estrogen-progestin vaginal ring andDMPA,
compared to nonhormonal contraception (copper IUD) use.
A neutral effect on sexual desire was found in women
using estrogen-progestin patch [64]. DMPA association with
a lower sexual function was also supported by users who
reported not finding sex pleasurable, compared to copper
IUD users, and feeling anxious before sex, but this last
difference was not statistically significant [64]. Nelson had
also reported that 5.8% of women using DMPA have negative
complaints on libido [65].
In contrast, no association was found between the use
of DMPA injection and sexual interest among adolescent
userswhen comparing various hormonal contraceptives [66].
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Another study that evaluated OC vs. injectable progestin
in their effect on sexual behavior found that COC users
had lower levels of FT compared with DMPA users, but
they were not different in sexual function [67]. Similarly,
no difference was found in sexual interest of an adolescent
population comparing DMPA users to nonusers of any
hormonal method of contraception [68].
3.3. Long-Acting Reversible Contraception. LARC methods
include LNG and copper IUDs, and the etonogestrel sub-
dermal implants. LARC provides at least three years of con-
tinuous pregnancy protection and is highly effective (>99%)
because it is not subject to errors in use that often reduce
effectiveness of SARC [69].
In most studies, hormonal IUD did not alter sexual func-
tioning, but some women who used an IUD had increased
sexual desire or an overall improvement in their sex life.
In a study of 200 women using the levonorgestrel-releasing
intrauterine system (LNG-IUD), a significant beneficial effect
of this method on sexual functioning (sexual desire and
arousal) was found, compared to control groups of women
using a different type of IUD and with women using no
contraception [70]. Other studies have also reported high
rates of satisfaction with both IUDs, hormonal and copper,
but no difference in sexual function [64, 71].
Available evidence on the sexual effects of the hormonal
IUD is based on the LNG-IUDwith total content of 52mg (20
mcg / 24 h). Until new data, it seems plausible to extrapolate
these results to the newest IUD containing 13.5 mg of LNG.
Data on contraceptive implants and sexual health are
more inconclusive. A lack of interest in sex was established in
women using the progestin implant versus the use of a non-
hormonal contraceptive [64]. Gezgine et al. found that 2.5%
of women had the implant removed due to decrease of libido
[72]. Anorgasmia after etonogestrel implant insertion as a
possible rare adverse event was reported, quickly reversible
with implant removal [73].
However, as already mentioned, nonoral hormonal con-
traception increased the positive indicators of female sexual
function in a number of studies [29, 60, 61]. Guida et al.
randomly assigned three groups of women to the contra-
ceptive ring, COC (20 mcg EE/150 mcg desogestrel), or a
control group. Women in both the ring and the COC group
reported a global improvement of sexual function compared
to women not using hormonal contraception [74]. These
three groups were later compared with a new group of
women, treated with a subdermal hormonal contraceptive
containing 68 mg etonogestrel. A significant increase in the
frequency of sexual intercourse, personal initiative, numbers
of orgasm, and satisfaction has been observed in the group
using subdermal hormonal contraception, compared to all
other groups. As authors recognized, the major limitation
of the study is that patients have been enrolled in two
different periods. Nevertheless, all hormonal contraceptives
tested seemed to have a positive effect on some aspects of
sexual function in the users. The authors also concluded
that subdermal hormonal contraceptive is better for women’s
sex life but its effect is slower compared to other hormonal
contraceptives, because the sexual increments were effective
only after six months [75]. In the same way, another study of
the etonogestrel implant showed no negative effects on libido
and on female sexual function [76].
4. Important Considerations about Sexual
Health of Hormonal Contraception Users
Prior to starting hormonal contraception, it is necessary to
evaluate the patient for contraindications and risks associated
with this group of contraceptives. Based on this assess-
ment and according to woman’s preference, a method is
recommended. It is also relevant to consider the impact
that various hormonal contraceptives may have on sexual
function when prescribing these methods to any woman.
In fact, an assessment of sexual problems should be a part
of every comprehensive woman’s health visit. Women who
discussed their sexual concerns with their clinician found
the discussion helpful. In a questionnaire study of over 1000
women seen for a primary care visit, 98% reported at least one
sexual complaint and only 18% of clinicians asked about their
sexual health [77].
The World Health Organization (WHO) and the United
States’ Centers for Disease Control and Prevention (CDC)
guidelines on contraceptive use do not mention the potential
effects of hormonal contraceptives on women's sexuality [78,
79]. Yet, screening patients for preexisting FSDand informing
them of the possible sexual side effects of hormonal contra-
ception are important [43]. In the largest United States study
of FSD, Prevalence of Female Sexual Problems Associated
with Distress and Determinants of Treatment Seeking (PRE-
SIDE), among approximately 3000 women identified with a
distressing sexual problem, only 6% scheduled amedical visit
specifically for a sexual complaint [6].
The mixed results on the interaction between the use of
hormonal contraception and female sexual function do not
allow absolute recommendations. However, possible sexual
side effects require that they be considered and,whenpresent,
a therapeutic approach should be initiated.
As here reviewed, COCs with association of DRSP/EE,
or gestodene/EE and LNG/EE, seem to be good choices for
women with sexual issues because FSD symptoms are less
likely to occur [27, 30, 44, 45, 47]. In daily clinical practice,
the choice of a progestogen with a more androgenic action to
enhance female sexual function seems to be a commonsense
choice rather than an evidence-based one. In this sense,
studies also suggest that women with COC-associated FSD
can improve several sexual domains after switching to a com-
bined E2V/DNG pill or to a COC containing E2/NOMAC
[56–58].
It is also true that concerns about the different dosages of
EE or about the elimination of the hormone-free interval in
modern oral contraceptives as modulatory factors of female
sexual function seem negligible [27–30, 47, 48].
Available evidence on the sexual impact of the hormonal
LARC methods seems reassuring, especially LNG-IUD [64,
70, 71]. Hormonal IUD presents as a possible first-line
alternative method of hormonal contraception to women
who experience FSD with SARCs and do not desire fertility
in a near future.
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Sexual domains should not only be evaluated before
starting hormonal contraception, but they should also be
reviewed regularly. Physicians should ask open-ended ques-
tions regarding sexual health, rather than wait for women
to initiate the conversation [80]. If left untreated, sexual
problems can have a negative impact on the quality of life,
self-esteem, and interpersonal relationships of these women.
A multidisciplinary approach, involving trained special-
ists and psychologists, is important when FSD is diag-
nosed. Conversely, hormonal contraception-related sexual
impairment, when early detected, will allow these women
to maintain reliable contraceptive choices, by having an
informed conversation with the physician and discussing
other options, as the switch of formulations or the route
of administration. Changes in desire and sexual satisfaction
during hormonal contraception are important elements that
might relate to acceptability, compliance, and continuation of
effective contraception [29, 36].
5. Concluding Remarks
Sexual specific effects of hormonal contraceptives are not well
studied.The literature shows significant disagreement among
studies on this topic, mainly because different methodologies
are used. Only a few reports have attempted to address
this issue amid immense scientific research into the adverse
effects of hormonal contraception. And most of those who
addressed sexual dysfunction in women did not assess
whether sexual issues are associated with personal distress,
a key finding for the diagnosis of FSD.
This review suggests that hormonal contraception can
cause female sexual response impairment. The how and to
whom are open critical questions. Estrogens and androgens
play a role in female sexual function, but the magnitude of
their effects needs further investigation. Several studies have
linked hormonal contraception to negative effects of sexual
function, but also to a neutral effect, or an improvement
in the sexual domains, compared to women who do not
use hormonal methods or who do not use any type of
contraception.
The multifaceted nature of female sexual function shows
the importance of ascertaining of a temporal relationship
between the onset of sexual complaints and initiation of
a hormonal contraceptive. There are so many factors that
affect the sexual response that the positive or negative impact
attributable to hormonal contraception can be covered. On
the other hand, the diagnosis of FSD requires a holistic
assessment where the use of a hormonal contraceptive can
sometimes be mistakenly regarded as the perfect suspect.
It is also clearly possible that the sexual behavioral
impact of exogenous administration of progestogens and/or
estrogens varies inwomen,whichwould explain that negative
or positive effects are restricted to subgroups. It is not yet
possible to predict which women are likely to experience
adverse effects of hormonal contraception on their sexuality,
nor which oral formulations or nonoral routes of administra-
tion are most likely to be responsible.
It is important to highlight the individuality of each
woman's sexual health, increasing the complexity of this field.
In order to improve compliance with hormonal contracep-
tives, it seems appropriate to incorporate women's sexual
health into contraceptive counseling and to maintain the
assessment of sexual function as an integral part of follow-
up consultations. Hormonal contraception is a milestone in
women's health and any approach to maximizing its benefits
should be a priority.
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